Posted 10/21/2024 1:16 AM (GMT -5)
This new drug candidate was developed by Prometheus Biosciences, a company founded in San Diego by some gastroenterologists and associates from Cedars-Sinai (Los Angeles) along with some researchers and biotech people in San Diego.
Although it's a different company than Prometheus Labs, the similar names should be a clue to readers that the companies are closely related, with many of the same principal people involved.
Merck bought out Prometheus Biosciences last year (2023) for about $10.8 billion based on the promise of this new treatment.